The specialty pharmaceutical maker that ran into production problems with the COVID-19 vaccine is sharply cutting back on operations at its East Baltimore plant. Emergent BioSolutions is also laying off more than 200 employees. Company officials report they’re also cutting 20 jobs at their drug product facility in Rockville. Emergent officials say they’re turning their focus to core products, such as Narcan nasal spray. They say they’re laying off 400 employees company-wide, including workers at a plant in Massachusetts because of changes in federal government procurements.